Uy Ear
Stock Analyst at Mizuho
(3.93)
# 674
Out of 4,735 analysts
59
Total ratings
41.18%
Success rate
16.1%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $19 → $20 | $13.08 | +52.91% | 13 | Jan 7, 2025 | |
| QURE uniQure | Maintains: Neutral | $7 → $20 | $14.91 | +34.14% | 4 | Dec 19, 2024 | |
| RLMD Relmada Therapeutics | Downgrades: Neutral | $23 → $1 | $0.37 | +169.47% | 1 | Dec 5, 2024 | |
| ALKS Alkermes | Maintains: Outperform | $35 → $40 | $30.10 | +32.89% | 5 | Nov 13, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $18 → $16 | $6.94 | +130.55% | 2 | Jul 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $40 | $19.85 | +101.51% | 1 | May 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $145 → $179 | $116.79 | +53.27% | 5 | May 17, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $25 → $21 | $17.89 | +17.38% | 10 | May 9, 2024 | |
| EOLS Evolus | Maintains: Buy | $20 → $23 | $13.48 | +70.62% | 3 | Mar 8, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Neutral | $116 → $140 | $145.88 | -4.03% | 10 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $16 | $3.67 | +335.97% | 1 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $148.15 | -73.00% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.60 | +284.62% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $0.75 | +300.16% | 2 | Mar 1, 2023 |
Arcutis Biotherapeutics
Jan 7, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $13.08
Upside: +52.91%
uniQure
Dec 19, 2024
Maintains: Neutral
Price Target: $7 → $20
Current: $14.91
Upside: +34.14%
Relmada Therapeutics
Dec 5, 2024
Downgrades: Neutral
Price Target: $23 → $1
Current: $0.37
Upside: +169.47%
Alkermes
Nov 13, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $30.10
Upside: +32.89%
Sage Therapeutics
Jul 19, 2024
Maintains: Neutral
Price Target: $18 → $16
Current: $6.94
Upside: +130.55%
Cartesian Therapeutics
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $19.85
Upside: +101.51%
Sarepta Therapeutics
May 17, 2024
Maintains: Buy
Price Target: $145 → $179
Current: $116.79
Upside: +53.27%
ACADIA Pharmaceuticals
May 9, 2024
Maintains: Neutral
Price Target: $25 → $21
Current: $17.89
Upside: +17.38%
Evolus
Mar 8, 2024
Maintains: Buy
Price Target: $20 → $23
Current: $13.48
Upside: +70.62%
Neurocrine Biosciences
Feb 8, 2024
Maintains: Neutral
Price Target: $116 → $140
Current: $145.88
Upside: -4.03%
Nov 22, 2023
Maintains: Buy
Price Target: $35 → $16
Current: $3.67
Upside: +335.97%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $148.15
Upside: -73.00%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.60
Upside: +284.62%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $0.75
Upside: +300.16%